We protect your health through science
Investigation
Antibiotic Resistance
Research Lines
Content with Investigacion .
Hepatitis
- Diseño de métodos diagnósticos para el estudio de los virus de las hepatitis (VH) A, B, C, D, E: Diseñamos sistemas de PCR para su detección y caracterización.
- Evaluación de métodos diagnósticos de los VH. Colaboramos con empresas para estudios de sensibilidad y especificidad de equipos diagnósticos.
- Estudios de Seroprevalencia de los virus de las hepatitis.
- Epidemiología genómica de genomas completos de VHA, VHB, VHC, VHD y VHE en colaboración con el ECDC. Estudios de trazabilidad del VHE.
- Caracterización molecular de virus de las hepatitis mediante secuenciación masiva: a) VHB: mutantes de escape HBsAg (prevalencia y efectos en la detección del HBsAg). Estudio de mutaciones en epítopos de estimulación inmune y mutaciones asociadas a evolución clínica desfavorable.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
c) Estudios filogenéticos del VHD.
d) Análisis genómico del VHE.
e) Investigación etiológica de hepatitis no filiadas mediante estudios de metagenómica.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
Research projects
Content with Investigacion .
1. Proyecto CIBEREPS 2022. Microbiological and genomic investigation of hepatitis in children by metagenomic approach in case and control subjects (IP: Ana Avellón).
2023-2024. En colaboración con el Hospital San Joan de Deu de Barcelona.
2. MPY 501-19: Tracking hepatitis E virus infection by means of epidemiological research and whole genome sequencing. Project TrazHE. (IP: Ana Avellón). 2020-2024.
3. Proyecto CIBEREPS 2021 Metagenomic sequencing to identify viral aetiologies in undiagnosed paediatric cases of meningitis and encephalitis (IP: D. Tarragó). 2021-2022.
4. MPY 383/19 (PEJ2018-004446-A). Ayudas para la promoción de empleo joven e implantación de la garantía juvenil en I+D+I. análisis de la complejidad de secuencias de los virus de la hepatitis A, B, C; D y E (VHA, VHB, VHC, VHD y VHE) mediante técnicas de secuenciación masiva. (IP: Ana Avellón). 2020-2021.
5. MPY 1285/16 Movilidad "Salvador de Madariaga" programa estatal de promoción de talento y su empleabilidad. (IP: Ana Avellón). 2016.
Publications
Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?
9. Ceballos F; Ryan P; Blancas R; et al; Fernández-Rodríguez A (AC); Jiménez-Sousa MA. (19/20). 2021. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? Frontiers in Medicine. Frontiers. 8-718053.
DOITelomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals
12 . Molina-Carrión S; Brochado-Kith, Oscar; González-García J; et al; Angeles Jimenez-Sousa, Maria. (16/16). 2020. Telomere length increase in HIV/HCV-coinfected patients with cirrhosis after HCV eradication with direct acting antivirals. JOURNAL OF CLINICAL MEDICINE. MDPI. ISSN 2077-0383.
DOIMicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
15. Brochado-Kith, Oscar; Gomez-Sanz, Alicia; Real LM; et al; Fernandez-Rodriguez, Amanda (AC). (16/16). 2019. MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection JOURNAL OF CLINICAL MEDICINE. MDPI. 7. ISSN 2077-0383.
DOIPersistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination. Rodríguez-Mora S, Pérez-Lamas L, Solera Sainero M, Torres M, Sánchez-Menéndez C, Corona M, Mateos E, Casado-Fernández G, Alcamí J, García-Pérez J, Pérez-Olmeda M, Murciano-Antón A, López-Jiménez J, García-Gutiérrez V, Coiras M (AC). Cancers 2023, 15(8), 2344. doi: 10.3390/cancers15082344. PMID: 37190272.
PUBMED DOIContent with Investigacion .
-
Horacio Gil Gil
Research Scientist
ORCID code: 0000-0002-7114-6686
Degree in Veterinary Medicine in 1995 and PhD in Veterinary Medicine in 2002 from the University of Zaragoza. He did his PhD thesis at NEIKER Tecknalia (Derio, Vizcaya) and the National Center for Microbiology of Instituto de Salud Carlos III (CNM-ISCIII, Majadahonda, Madrid) on the biological cycle of Lyme disease in the Basque Country. After that, he developed his postdoctoral training in different aspects of the pathogenesis of tularemia at the Center for Infectious Diseases, Stony Brook University, New York (USA) for 3 years. In December 2005, he joined the Reference and Research Laboratory in Special Pathogens of the CNM-ISCIII where he developed diagnostic, reference and research activities, in Bartonella, Leptospira and pathogens of interest in bioterrorism. Between 2014-2016 he participated in the European Program for the Training of Microbiologists in Public Health (EUPHEM), organized by the European Centre for Disease Prevention and Control. During this program, he participated in an international mission for the investigation of a cholera outbreak in Ghana, proposed by the Bernhard Nocht Institute for Tropical Diseases in Hamburg (Germany). In December 2016, he worked as a laboratory consultant for the World Health Organization at their office in Phnom Penh (Cambodia). Subsequently, he worked one year with Médecins Sans Frontières as director and quality manager of the TB laboratory in Nukus (Uzbekistan).
In 2019, he joined the HIV Variability and Biology Unit at CNM-ISCIII, where he developed different reference and research activities, including his contribution to the molecular epidemiological surveillance of HIV-1 in Spain and the study of HIV-1 antiretroviral resistance. Since September 2022 he has been leading the Human Papillomavirus Unit at the CNM-ISCIII. -
Alicia Inés García Señán
Predoctoral Student UNED
Degree in Pharmacy in 2013 from the Complutense University of Madrid. She completed specialized health training in Microbiology and Parasitology at the Complejo Asistencial Universitario de Salamanca (2014-2018). During this period he studied a master's degree in Tropical Diseases at the University of Salamanca (2016). She has developed her professional activity as a clinical microbiologist at the Hospital de Santa Bárbara (Soria) (2018), Hospital Universitario Vall d'Hebrón (Barcelona) (2019-2022), and Hospital Central de la Defensa (Gómez Ulla) C.S.V.E, since 2022. In September 2024 she has started PhD studies at the Human Papillomavirus Unit of the CNM-ISCIII.
-
Manuela Rodríguez Vargas
Técnico de Laboratorio
List of staff
Additional Information
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.